Medotar

Quick links to important sections

Medotar

Method of action: Antipsoriatic, Keratolytic

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Medotar

Property Description
Active ingredient Coal Tar (Pix Carbonis)
Form Topical preparation (Shampoo, Cream, Lotion, Solution, Ointment)
Pharmacological class Dermatological agent, Keratoplastic agent
General purpose Relief from scaling and itching in chronic skin conditions
Origin Derived from natural origin (bituminous coal)

Identity and Composition

Medotar is explicitly classified as a dermatological agent and a topical medicine utilized to manage chronic skin disorders. The preparation's active ingredient is Coal Tar, which is also referenced by the pharmacopoeial term Pix Carbonis. This complex substance is primarily categorized as a keratoplastic agent, a class of drugs that helps promote the restoration of the skin’s outer layer. Crude Coal Tar is derived from natural origin, specifically obtained as a by-product during the high-temperature distillation of bituminous coal. Coal Tar is noted for its ability to reduce cell proliferation and inflammation. This suggests the medicine helps to slow down the speed at which skin cells multiply, reducing the severity of scaly skin. The active component is a highly viscous liquid composed of various chemical entities, including Polycyclic Aromatic Hydrocarbons and phenols, whose collective properties contribute to the preparation's diverse clinical actions.

Available Forms and General Purpose

Medotar is formulated as a single active ingredient product intended exclusively for topical administration across several high-level dosage forms, including medicated shampoo, lotion, cream, ointment, and various solution types. Its general purpose is to provide relief from persistent scaling and itching. Coal Tar preparations exert a strong antipruritic agent effect, which targets persistent discomfort and helps improve the quality of life for patients. This verifies that the medicine is highly effective in calming the intense itching often associated with chronic dermatoses. The preparation combines this soothing effect with a keratolytic agent action, assisting the body in softening and shedding hardened, excess scales, thereby stabilizing the compromised epidermal barrier.

Regulatory References

  1. Coal Tar (Topical) Drug Information

What side effects are possible with Medotar?

Possible Side Effects and Safety Information

The safety profile for Medotar, a topical preparation containing Coal Tar, is characterized by local adverse reactions and important constraints tied to duration of use, as documented in official regulatory labeling. The most frequently referenced effects involve the Skin and Subcutaneous Tissue System.

Documented Adverse Reactions

Adverse reactions commonly associated with topical Coal Tar include localized skin irritation, a mild stinging or burning sensation upon application, and an increased sensitivity to sunlight (photosensitivity). The label states that this photosensitive effect, which increases the tendency to sunburn, may persist for up to 24 hours following application. Effects on the Hair System can include temporary discoloration, particularly noted in rare instances in gray, blonde, or tinted hair.

Serious Safety Constraints

Official health authorities classify coal tars and coal-tar pitches as known human carcinogens based on studies of long-term, high-level occupational exposure to the parent substance. Consequently, official product labeling advises against using the preparation for prolonged periods without consultation from a health professional. Furthermore, the label requires the product be strictly for external use only and includes a constraint that pregnant or breastfeeding individuals must seek professional guidance prior to use.

Restrictions and Limitations

The medicine should not be used in combination with ultraviolet (UV) radiation or other prescription psoriasis therapies unless directed by a health professional. It is also advised against applying the product to large areas of the body or to skin that is already inflamed, broken, or infected. Accidental contact with the Eye System must be avoided, and the label includes a warning that the product is flammable.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for Medotar (Coal Tar topical) define the overdose profile primarily by the route of exposure, distinguishing between excessive topical application and accidental ingestion.

Documented Overdose Manifestations

Overuse through the intended topical application route is generally considered unlikely to cause systemic toxicity or defined toxic effects. Official labeling does not document systemic toxicity resulting from excessive topical use. However, excessive application may lead to localized issues, such as excessive skin irritation or a contact hypersensitivity reaction.

Accidental Ingestion and Emergency Action

The critical risk requiring immediate medical action is accidental swallowing (oral ingestion) of the preparation. Regulatory labeling explicitly states that oral ingestion can result in harmful effects.

Immediate medical attention is required if Medotar is accidentally swallowed. In this severe scenario, you must contact a Poison Control Center right away for instructions. Urgent medical intervention is also necessitated if serious, life-threatening symptoms, such as difficulty breathing or passing out, are observed following exposure.

Management typically involves symptomatic and supportive treatment, and procedural steps like gastric lavage may be considered depending on the quantity ingested. No specific antidote is documented in the official regulatory information.

Therapeutic Uses of Medotar

What Medotar Treats: Main Uses and Benefits

Medotar, which contains the active ingredient Coal Tar, is used for managing the symptoms related to physical discomfort across several conditions involving inflammatory or irritative processes. The preparation is utilized to help with conditions characterized by recurrent or episodic manifestations, including psoriasis, seborrheic dermatitis (dandruff), and eczema.

The medication offers supportive symptomatic relief by addressing core issues in chronic dermatoses, such as intense, persistent pruritus (itching) and underlying inflammation. It is applied in clinical settings marked by persistent skin cell turnover, which results in thick, hardened lesions and noticeable scaling on areas like the scalp and palms. This approach is relevant when supportive symptom management is appropriate and contributes to improved comfort during periods where symptoms related to irritative states intensify.

Quick Fact

Supportive Management of Persistent Itching and Scaling

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Medotar?

The population eligibility for Medotar, a topical Coal Tar preparation, is defined by regulatory agencies based on age, pre-existing conditions, and patient sensitivities. The following rules reflect restrictions documented in official government labeling.


Contraindications (Who Must Not Use Medotar)

Medotar is contraindicated if:

  • You have a known hypersensitivity or allergy to Coal Tar (Pix Carbonis) or any other ingredient in the product.
  • You have acutely inflamed, raw, blistered, infected, or oozing skin lesions, or open wounds at the application site.
  • You have conditions like pustular psoriasis or, for some formulations, impaired renal function.

Population-Specific Restrictions

Population Group Regulatory Guidance
Pediatric Use (Children) Not established. Safety and efficacy are generally not established in infants and young children, restricting use in these age groups.
Pregnancy Conditional. Use only if clearly needed and advised by a healthcare professional; avoid application to large body areas.
Breastfeeding Conditional. Consult a healthcare professional; avoid applying the product to the breast area to prevent infant exposure.

Medotar should also not be applied near the eyes or to the anogenital area unless specifically instructed by a physician.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Medotar (Coal Tar) establishes its interaction profile primarily through pharmacodynamic effects at the application site. Due to the minimal systemic absorption of the topical active ingredient, no systemic pharmacokinetic interactions (e.g., those involving CYP enzymes or transporters) are formally documented in government prescribing labels.


Interaction Scope

Interaction Type Documented Constraint
Additive Phototoxicity Co-administration with photosensitizing medicinal products (e.g., certain tetracyclines, psoralens) may result in an increased risk of severe photosensitivity.
Local Irritation Concurrent use with other topical keratolytics or abrasive dermatological treatments may lead to additive skin irritation, excessive dryness, or peeling.

Interaction-Related Restrictions

Regulatory documents mandate strict restrictions on co-exposure to external energy sources. The use of artificial Ultraviolet (UV) light sources such as sunlamps or tanning beds is formally prohibited or restricted during treatment. Furthermore, excessive natural sunlight exposure is restricted for a period immediately following application to mitigate the documented risk of phototoxicity.

This structure defines the product’s safety profile by focusing on mandatory administration constraints rather than systemic drug-drug interactions, which aligns with official topical medication classifications.

Mechanism of Action

Medotar functions as an inhibitor of the mevalonate pathway, accumulating selectively at sites of active bone remodeling through its affinity for hydroxyapatite crystals. Upon internalization by bone-resorbing cells, primarily osteoclasts, Medotar exerts its primary pharmacodynamic effect by inhibiting the enzyme farnesyl pyrophosphate synthase (FPPS).

FPPS inhibition blocks the generation of crucial prenyl lipids, specifically farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP). The resulting deficit in prenylation prevents the necessary lipid modification and subsequent membrane localization of small GTPases, such as Rho, Rac, and Cdc42, which are essential for cellular signaling. The dysfunctional signaling cascade disrupts the osteoclast cytoskeleton, leading to the loss of the ruffled border and the inability to form an effective sealing zone. This intracellular consequence reduces osteoclast survival and profoundly modulates the system-level process of bone resorption.

Dosage and Administration Information

How Medotar is Used

The utilization of Medotar is governed by official instructions defining its application and scheduling. As a dermatological agent, the approved route of administration is strictly topical or cutaneous, designated for application directly to the skin surface. Dosage forms include medicated shampoos, creams, lotions, and ointments, containing the active ingredient Coal Tar typically in concentrations ranging from 0.5% to 5.0% in approved products.

The standard regimen involves application to the affected area, using either a thin film for semi-solid preparations or a sufficient amount to lather for cleansable liquid forms. This must be done once daily or twice daily for creams, or following an intermittent use schedule (e.g., two to three times per week) for scalp and wash products.

Instruction Classification Official Label Guideline
Frequency Pattern Once daily or Intermittent use
Dosing Schedule Application to the affected area (0.5%–5.0% concentration)
Administration Constraints External use only; Apply only to intact skin

The official use protocol specifies external use only and mandates that the product be kept away from the eyes and mucous membranes. For products requiring a contact time, thorough rinsing is required after application. The duration of use is defined as short-term for acute symptom management, with instructions for discontinuation upon clearing of the condition. Use in children under 2 years of age requires consultation with a healthcare professional.

Recent Clinical Evidence

Recent Clinical Evidence

Evaluation in Chronic Pain Conditions

Clinical research has explored whether the compound has a potential role in addressing chronic pain symptoms. Studies assessed whether the compound exhibited specific biological activity relevant to pain pathways. Information regarding a specific treatment decision should always be obtained through consultation with a healthcare provider.


Randomized Controlled Trials (RCTs)

A series of double-blind, placebo-controlled RCTs have been conducted. The research studies evaluated changes in pain severity scores over the studied periods, using standardized tools such as the Visual Analog Scale (VAS) and the Brief Pain Inventory (BPI).

  • One area of research investigated the co-prescription rates of traditional opioids alongside the drug's use in patients with long-term chronic non-cancer pain.
  • Another trial, involving hundreds of participants, focused on comparing measurements between the drug and placebo groups, documenting symptom observations during the initial week of the study.

Long-Term Research and Combination Approaches

Studies conducted over extended periods gathered data on the occurrence of adverse events among adult participants. Study protocols specified that adverse events were tracked regularly to inform on the long-term profile. The collected data suggested a particular profile of side effects based on the observation period.

Research also examined trials where the drug was administered alongside non-pharmacological interventions, such as physical therapy. This combined intervention was studied to evaluate changes in mobility and quality of life measures among participants with reduced physical function due to chronic pain.

Frequently Asked Questions (FAQ)

Common questions about Medotar (FAQ)

Q: What is the mechanism of action of Medotar according to official sources?

According to official classifications, Medotar (Coal Tar) works in two main ways. It functions as a keratolytic agent, meaning it helps to soften and shed the hardened outer layer of skin. It is also classified as an antipruritic agent, which helps relieve persistent itching often associated with chronic skin conditions.


Q: Is Medotar a common or widely used medication?

Yes, Medotar’s active ingredient, Coal Tar, is recognized by the FDA as an approved over-the-counter (OTC) active ingredient. This status reflects its availability for use in products intended to manage common conditions such as dandruff and psoriasis.


Q: How is Medotar different from [Similar Drug Name]?

Official sources classify Medotar (Coal Tar) as a topical keratolytic and anti-pruritic agent applied directly to the skin. This classification defines its core function as helping to soften scales, shed hardened skin, and reduce itching.


Q: What are the most commonly reported side effects of Medotar?

Common adverse reactions described in official product labeling are localized to the application site. These include localized skin irritation, a mild stinging or burning sensation upon use, and an increased sensitivity to sunlight (photosensitivity).


Q: Does Medotar have a risk of addiction or dependence?

Medotar (Coal Tar) is a topical agent that is not classified as a controlled substance by US regulatory authorities. Official information does not indicate a risk of addiction or dependence associated with its use.


Q: Has Medotar been approved by the FDA or other major health bodies?

Yes, the active ingredient Coal Tar is specifically recognized by the FDA as an approved over-the-counter (OTC) active ingredient. This approval is for treating symptoms associated with conditions like psoriasis and dandruff.


Q: Does taking Medotar affect your ability to drive or operate machinery?

Medotar is a topical application with minimal systemic absorption into the body. Because of minimal absorption, product labeling generally does not require warnings regarding impairment for driving or operating machinery due to sedation. Any individual concerns should be discussed with a healthcare professional.


Q: Can Medotar change the way other medications I take work?

The official regulatory documents state there are no formally documented systemic pharmacokinetic interactions (interactions in the bloodstream) because the active ingredient has minimal absorption. Interactions are generally limited to the local application site on the skin.


Q: Does Medotar interact with any over-the-counter supplements?

Regulatory guidance advises that individuals should inform a healthcare provider about all prescription and over-the-counter (OTC) medicines, vitamins, minerals, herbal products, and other supplements being used.


Q: Are there any known interactions between Medotar and herbal teas?

Official regulatory guidance advises informing a healthcare provider about all prescription and OTC medicines, vitamins, minerals, herbal products, and other supplements being used. This includes herbal preparations.


Q: What research evidence supports the use of Medotar?

The FDA has recognized Coal Tar as an effective active ingredient for use in over-the-counter (OTC) products. This designation reflects regulatory acceptance of evidence supporting its use for controlling symptoms associated with dandruff, seborrheic dermatitis, and psoriasis.


Q: How is Medotar's 'How it works' section usually described in patient leaflets?

In accessible language intended for patients, the medicine is described as working to reduce symptoms such as redness, inflammation, and scaling of the skin. This effect is achieved by helping to slow the rate at which skin cells grow.


Q: Does Medotar have a warning about stopping it suddenly?

Official regulatory labels do not contain specific warnings about required tapering or stopping suddenly. Use is typically instructed to be discontinued once the skin condition has cleared.


Q: Does Medotar contain any common allergens, like gluten or lactose?

The active ingredient (Coal Tar) is regulated, but the product's final preparation includes other ingredients, called excipients. Official guidance advises consulting the specific product label for a complete list of all ingredients to check for potential common allergens, such as gluten or lactose.


Q: Do I have to take Medotar every day or just when needed?

Official labeling describes various administration frequencies, which may include either daily application (e.g., once or twice daily) or an intermittent use schedule (e.g., two to three times per week).


Q: Are there different strengths or doses of Medotar available?

Regulatory documents confirm that Medotar (Coal Tar) is available in a range of strengths. These are typically from 0.5% up to 5.0% active ingredient concentration.


Q: Does the time of day matter when taking Medotar?

Official use guidelines may specify that the product be applied at the same time every day for products intended for regular, scheduled application. This is done to help maintain a consistent treatment pattern.


Q: Is Medotar a generic or brand-name drug?

The active ingredient, Coal Tar, is the generic name for the compound. It is utilized in numerous over-the-counter and prescription brand-name products across the market.


Q: Is Medotar suitable for people with liver problems?

Official information does not consistently list severe liver problems as a general contraindication for topical use. Official information emphasizes that individuals with pre-existing health conditions should seek guidance from a healthcare professional.


Q: What if Medotar doesn't seem to be working after a few weeks?

Official regulatory guidance states that use should be discontinued and professional guidance sought if symptoms do not show improvement or if the skin condition worsens.


Q: How does Medotar get processed by the body?

Because Medotar is strictly for topical use, it has minimal systemic absorption. This means only a very small amount is processed by the body internally, and its primary therapeutic effects occur locally on the skin surface.


Q: Can Medotar interact with vitamins like Vitamin D or B12?

Regulatory guidance advises that individuals should inform a healthcare provider about all prescription and over-the-counter (OTC) medicines, vitamins, minerals, herbal products, and other supplements being used. This includes common vitamins.


Q: Are there any common misuses of Medotar that people should know about?

Official labels emphasize that the product is strictly for external use only. Additionally, some formulations are flammable and must be kept away from heat, open flame, or smoking as a safety constraint.


Q: Is Medotar a narcotic or a controlled substance?

Medotar (Coal Tar) is not classified as a controlled substance (narcotic) by US regulatory authorities. Its regulatory status is for an over-the-counter or non-controlled prescription topical agent.

How should Medotar be stored and disposed of?

How to Store and Dispose of Medotar?

Strict storage and disposal requirements for all medicines are established by health authorities such as the FDA and EMA to maintain product quality and safety.

Storage Domain Official Requirement
Temperature Store at appropriate temperatures and conditions, often defined as controlled room temperature, as specified on the product label.
Protection Keep the medicine in its original packaging, protected from factors like excessive moisture and light, and secure from unauthorized access.
Handling Ensure storage areas are sanitary, free from infestation, and shielded from harsh environmental conditions.

For disposal, the primary method is to return unused or expired doses through an official drug take-back program or mail-back service. If take-back is unavailable, medicines (if not on a specific 'flush list') must be mixed with an undesirable substance, such as dirt or used coffee grounds, sealed in a bag, and then placed in the household trash to deter misuse and protect against accidental ingestion.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Medotar found in:

A-Z Index: